Nxera Pharma
Manufacturing · Japan · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Pmo Hanzomon 11TH Fl 2-1, Tokyo, Tokyo, ...Phone Number
+81 352103290Website
nxera.lifeRevenue
$103.5 MillionIndustry
About Nxera Pharma
Nxera Pharma Org Chart
Is Nxera Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Nxera Pharma has new funding data
Nxera Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Nxera Pharma
Check out if Nxera Pharma is spiking on competitors!
Check if Nxera Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nxera Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Nxera Pharma launches new products
Click to see if Nxera Pharma had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Nxera Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Nxera Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nxera Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nxera Pharma.
Nxera Pharma Tech Stack
A closer look at the technologies used by Nxera Pharma
Most Recent Scoops
Nxera Pharma News & Media
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognisedNxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
Tokyo, Japan and Cambridge, UK, 7 August 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June 2026. The full report can be found here.Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 AugustNxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nxera Pharma
Nxera Pharma is dedicated to accelerating the development of life-changing medicines through investments in science and technology. Utilizing their proprietary NxWave platform, they focus on rational structure-based drug design to unlock the potential of GPCRs. The company aims to provide better treatment options for patients in need and is activel... Read More